<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink">
    <mets:dmdSec ID="DMD_5f4fd588-6773-446c-a1ca-712ae4ec20db">
        <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
            <mets:xmlData>
                <mods xmlns="http://www.loc.gov/mods/v3" version="3.7" xmlns:vl="http://visuallibrary.net/vl">
                    <titleInfo lang="eng">
                        <title>Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome</title>
                    </titleInfo>
                    <name type="personal">
                        <displayForm>Fröb, Elisabeth J.</displayForm>
                        <namePart type="family">Fröb, Elisabeth J.</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal">
                        <displayForm>Sindermann, Jürgen</displayForm>
                        <namePart type="given">Jürgen</namePart>
                        <namePart type="family">Sindermann</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal" authority="gnd" authorityURI="http://d-nb.info/gnd/" valueURI="http://d-nb.info/gnd/1173905731">
                        <displayForm>Reinecke, Holger</displayForm>
                        <namePart type="given">Holger</namePart>
                        <namePart type="family">Reinecke</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <name type="personal">
                        <displayForm>Tuleta, Izabela</displayForm>
                        <namePart type="given">Izabela</namePart>
                        <namePart type="family">Tuleta</namePart>
                        <role>
                            <roleTerm type="code" authority="marcrelator">aut</roleTerm>
                        </role>
                    </name>
                    <typeOfResource>text</typeOfResource>
                    <genre authority="dini">article</genre>
                    <originInfo>
                        <dateIssued encoding="w3cdtf" keyDate="yes">2022-01-29</dateIssued>
                        <dateIssued encoding="w3cdtf">2022-11-09</dateIssued>
                    </originInfo>
                    <language>
                        <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
                    </language>
                    <abstract lang="eng">Background: Currently, data on sacubitril/valsartan therapy from the real-world settings are scarce and the predictors of a good clinical responsiveness to this drug are unknown. Objectives: To assess efficacy and safety profile of sacubitril/valsartan and to identify predictors for a better clinical outcome. Materials and methods: Clinical, laboratory and echocardiographic data of 95 chronic heart failure (CHF) patients with reduced ejection fraction (HFrEF) were retrospectively analyzed. A good efficacy of sacubitril/valsartan was defined as the fulfilment of at least 2 of the following criteria: improvement of left ventricular ejection fraction (LVEF) or functional status, and reduction of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels or hospitalization rates. Results: Under sacubitril/valsartan, major improvements were observed in LVEF, the New York Heart Association (NYHA) class, NT-proBNP levels, and hospitalization rates. Patients with a good efficacy of sacubitril/valsartan were characterized by initially worse LVEF (median (interquartile range (IQR)): 29.0% (23.0–33.0%) compared to 32.0% (28.5–38.0%) with more frequent nonischemic etiology (65.4% compared to 41.9%) and hospitalizations for CHF/month (0.016 (0.004–0.057) compared to 0.000 (0.000–0.012)), lower cholesterol (42.3% compared to 65.1%), higher C-reactive protein (CRP) levels at baseline (0.5 mg/L (0.5–1.0 mg/L) compared to 0.5 mg/L (0.5–0.5 mg/L)), and a shorter timespan between CHF diagnosis and the start of sacubitril/valsartan treatment (66.0 (11.0–127.0) compared to 111 (73.0–211.0) months) (p &lt; 0.05 each). In a multivariate Cox analysis, only the last 2 parameters were shown to be independent predictors of good clinical responsiveness to sacubitril/valsartan (hazard ratio (HR) = 1.263, 95% confidence interval (95% CI) = [1.048; 1.521]; HR = 0.992, 95% CI = [0.987; 0.997], p &lt; 0.05, respectively). Conclusions: Sacubitril/valsartan improved LVEF, NYHA class, NT-proBNP levels, and hospitalization rates, mostly without relevant side effects. The independent predictors of a good clinical efficacy were higher CRP levels at baseline and a shorter delay between CHF diagnosis and the initialization of sacubitril/valsartan therapy.</abstract>
                    <note type="citation/reference">Adv Clin Exp Med. 31 (2022) 5, 475-487</note>
                    <note>Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster).</note>
                    <subject lang="eng">
                        <topic>CRP</topic>
                        <topic>Sacubitril/valsartan</topic>
                        <topic>NYHA class</topic>
                        <topic>Chronic heart failure with reduced left ventricular ejection fraction</topic>
                        <topic>Hospitalization rates</topic>
                    </subject>
                    <classification authority="ddc">610</classification>
                    <identifier type="urn">urn:nbn:de:hbz:6-32029528456</identifier>
                    <identifier type="doi">10.17879/32029706419</identifier>
                    <accessCondition type="use and reproduction" xlink:href="http://creativecommons.org/licenses/by/3.0/">CC BY 3.0</accessCondition>
                    <recordInfo>
                        <recordIdentifier>muenster_miami_5f4fd588-6773-446c-a1ca-712ae4ec20db</recordIdentifier>
                    </recordInfo>
                    <extension>
                        <vl:doctype>oaArticle</vl:doctype>
                    </extension>
                </mods>
            </mets:xmlData>
        </mets:mdWrap>
    </mets:dmdSec>
    <mets:fileSec>
        <mets:fileGrp USE="pdf upload">
            <mets:file MIMETYPE="application/pdf" ID="FILE_5f4fd588-6773-446c-a1ca-712ae4ec20db_1">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/5f4fd588-6773-446c-a1ca-712ae4ec20db/10.17219_acem145664.pdf" LOCTYPE="URL"/>
            </mets:file>
        </mets:fileGrp>
    </mets:fileSec>
    <mets:structMap TYPE="LOGICAL">
        <mets:div TYPE="document" ID="muenster_miami_5f4fd588-6773-446c-a1ca-712ae4ec20db" DMDID="DMD_5f4fd588-6773-446c-a1ca-712ae4ec20db">
            <mets:fptr FILEID="FILE_5f4fd588-6773-446c-a1ca-712ae4ec20db_1"/>
        </mets:div>
    </mets:structMap>
</mets:mets>
